Novartis now expects its core operating profit to grow in the mid to high teens, after second-quarter results outpaced analysts’ expectations, boosted by revenue from its blockbuster treatments.
Related Posts
Universal Plans Early Summer Launch of New Park With Marquee Harry Potter Ride
The earlier-than-expected opening raises the stakes in Comcast’s theme-park rivalry with Disney in Florida.
FTC Accuses Drug Middlemen of Inflating Insulin Prices
The Federal Trade Commission sued the drug middlemen that health plans use to keep a lid on drug spending, accusing the firms of inflating the […]
Danone Keeps Outlook as Consumers Welcome Lower Prices
Danone backed its full-year sales guidance as it eased the pace of price hikes and saw shoppers begin to buy more of its branded products.